Apligraf® is an FDA-approved bioengineered living cell therapy indicated for the healing of venous leg ulcers and diabetic foot ulcers.
• Stimulates healing due to tissue engineered structure, which includes an outer layer of protective skin cells (human epidermal keratinocytes) and an inner layer of cells (human dermal fibroblasts) contained within a collagen matrix
• Mechanism of action clinical study demonstrated that living keratinocytes and fibroblasts produce potent healing signals to convert the wound from a chronic to an acute state
• Proven to heal more venous leg ulcers faster in a randomized controlled trial and in the real-world setting
Apligraf® is indicated for use with standard therapeutic compression for the treatment of non-infected partial- and full-thickness skin ulcers due to venous insufficiency of greater than one month duration and which have not adequately responded to conventional ulcer therapy.
Apligraf® is also indicated for use with standard diabetic foot ulcer care for the treatment of full-thickness neuropathic diabetic foot ulcers of greater than three weeks duration which have not adequately responded to conventional ulcer therapy and which extend through the dermis but without tendon, muscle, capsule or bone exposure.
Apligraf® is contraindicated for use on clinically infected wounds. Contraindicated in patients with known allergies to bovine collagen or with a known hypersensitivity to the components of the Apligraf® agarose shipping medium.
If the expiration date or product pH (6.8-7.7) is not within the acceptable range DO NOT OPEN AND DO NOT USE the product. A clinical determination of wound infection should be made based on all of the signs and symptoms of infection. See full package insert for additional information.
All reported adverse events, which occurred at an incidence of greater than 1% in the clinical studies, are listed in Table 1, Table 2 and Table 3 in the full package insert. These tables list adverse events both attributed and not attributed to treatment. See full package insert for additional information.
Apligraf® has been processed under aseptic conditions and should be handled observing sterile technique. It should be kept in its tray on the medium in the sealed bag under controlled temperature 68°F-73°F (20°C-23°C) until ready for use. See full package insert for additional information.
|Assigned HCPCS code||●|
|Shelf life greater than 2 years|
|Shelf life limited|
|Indicated for acute wounds|
|Indicated for chronic wounds|
|Indicated for diabetic ulcers||●|
|Indicated for pressure ulcers|
|Indicated for surgical wounds|
|Indicated for third-degree burns|
|Indicated for venous ulcers||●|
|Contact manufacturer for usage guidelines|
|Educational Material Available||●|
|Free Samples/Trials Available|
|Published Clinical Article Available||●|
Diabetic Foot Ulcers
Venous Leg Ulcers
Apligraf® should be applied to a clean, non-infected, debrided wound after thoroughly irrigating the wound with a non-cytotoxic solution.
Before opening the Apligraf® package, check the expiration date and pH to ensure it is within range.
Open the package and remove Apligraf® using an aseptic technique.
Apligraf® must be used within 15 minutes of opening.
Apligraf® rests on a polycarbonate membrane. Be sure not to inadvertently remove it with Apligraf®.
Place Apligraf® directly over the wound, glossy side down, so the edges overlap with the wound edges.
Using a saline-moistened cotton tip applicator, smooth Apligraf® onto the wound bed so there are no pockets or wrinkled edges.
Adequately secure Apligraf® to ensure contact with the wound bed.
Cover Apligraf® using a non-adhesive primary dressing.
Apply a secondary non-occlusive dressing to create a bolster.
Upon complete wound closure, patients with venous leg ulcers should continue with compression therapy and patients with diabetic foot ulcers should continue to wear appropriate pressure relieving footwear and utilize other ulcer preventive foot care practices. See full package insert for additional information.
Not made with natural rubber latex
Organogenesis is a global leader in advanced wound care, offering a comprehensive portfolio of regenerative medicine products capable of supporting patients from early in the wound healing process through to wound closure, regardless of wound type.